1. Home
  2. SDEV vs HBIO Comparison

SDEV vs HBIO Comparison

Compare SDEV & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDEV

Stablecoin Development Corporation Common Stock

N/A

Current Price

$1.15

Market Cap

33.1M

Sector

Health Care

ML Signal

N/A

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$5.92

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDEV
HBIO
Founded
N/A
1901
Country
United States
United States
Employees
4
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
33.1M
26.5M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
SDEV
HBIO
Price
$1.15
$5.92
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$18.00
AVG Volume (30 Days)
744.6K
10.8K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.38
52 Week High
$1.60
$7.50

Technical Indicators

Market Signals
Indicator
SDEV
HBIO
Relative Strength Index (RSI) 48.06 46.00
Support Level $1.05 $5.77
Resistance Level $1.58 $6.70
Average True Range (ATR) 0.11 0.26
MACD -0.02 -0.02
Stochastic Oscillator 11.63 8.21

Price Performance

Historical Comparison
SDEV
HBIO

About SDEV Stablecoin Development Corporation Common Stock

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: